Vanda loses Hetlioz patent court decision, vows to appeal and ask for stay on Teva, Apotex competitors
A federal judge invalidated four of Vanda Pharmaceuticals’ patents for sleep med Hetlioz on Tuesday, effectively opening the door to generic tasimelteon competition from Teva, Apotex and others. Vanda plans to appeal and is asking for a stay against the competition in the meantime.
“Vanda intends to appeal the decision to the United States Court of Appeals for the Federal Circuit and to request a stay of market entry by Teva and Apotex while the appeal is pending,” the company said in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.